Clinical Trial Update: Basal Plus GLP1-ra on Glycemic Variability in CKD [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated adding a GLP-1 receptor agonist to basal insulin to reduce glycemic variability in individuals with diabetes and diabetic kidney di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Kidney Disease

Drugs mentioned

• Basal insulin (basal insulin)
• GLP-1 receptor agonist

Snippet

Sponsor: Elaine Chow | Conditions: Diabetes Mellitus, Diabetic Kidney Disease | Phase 4 | Status: COMPLETED